March 13, 2026- Abbott announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology had better glucose outcomes than those using traditional fingersticks. Improvements were achieved through participant-led self-management, guided by real-time CGM insights. Findings were presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).
About 63 million people worldwide rely on insulin to manage Type 2 diabetes, but real-world studies show only 18%–30% of those using basal insulin are reaching their HbA1c goals. This gap contributes to an estimated $217 billion in annual diabetes healthcare costs, indicating millions of people still need support to reach healthy glucose ranges. The FreeDM2 randomized controlled trial was designed to determine whether real-time continuous glucose monitoring can help people using basal insulin improve their glucose management.